Articles related to Pediatrics

Recent findings suggest that a slow up-dosing strategy in peanut oral immunotherapy for young children may offer a safer and more effective approach to managing peanut allergies.

In a phase 3 trial, oral sebetralstat demonstrated a median time to beginning of symptom relief of 1.61 hours for the 300 mg dose and 1.79 hours for the 600 mg dose, compared to 6.72 hours for placebo in hereditary angioedema attacks.

A recent study shows that combining meal replacement therapy with financial incentives led to a 6 percentage point greater reduction in BMI for adolescents with severe obesity compared to meal replacement therapy alone.

Early use of high-efficacy disease-modifying therapies in pediatric-onset MS patients with minimal disability reduces the risk of progression by 59% compared to no treatment.

Roflumilast cream 0.15% demonstrates rapid and significant improvement in itch within 24 hours of the first application, addressing a primary concern for atopic dermatitis patients.

CBD gummies offer a convenient administration method with prolonged effects, but their delayed onset presents unique considerations for therapeutic use. Understanding the pharmacokinetics and individual factors affecting CBD absorption is essential for optimizing patient outcomes.